SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
OVID

Ovid Therapeutics Inc. (NASDAQ:OVID)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$2.20-$0.14 (-5.98%)
 
Market cap
$415M
Insider Score
Health Score
Analyst consensus
Listed since
May 5, 2017
Website
Market Cap$415.21M+57.1%
Revenue (ttm)$1.45M-78.0%
Net Income-$43.11M-18.7%
EPS-$0.18+64.4%
Shares Out188.73M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,833,192
Open$2.26
Previous Close$2.34
Day's Range$2.17 - $2.33
52-Week Range$1.26 - $3.11
Beta0.24
AnalystsBuy
Price Target$6.25(+184.09%)
Earnings DateMar 15, 2027

About OVID

Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.

Address
Hudson Commons, New York City, NY, 10001, US
Market Cap
415 million
Employees
23
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$29.29K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
1 Buy0 Hold0 SellAvg target $6.50 (+192.8%)

1 firm rating OVID in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Weak
From OVID’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-5.98%
5 Days
-12.70%
1 Month
-10.93%
6 Months
-9.84%
1 Year
+57.14%

$OVID stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in OVID holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by OVID's directors and management

Net Shares Purchased by Insiders−30k−15k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

OVID Estimated quarterly lobbying spending

Source: U.S. Senate LDA

OVID Revenue by Segment

$13.68MTotal
OV329$6.56M47.98%
OV4071$3.75M27.42%
Legal and professional fees$2.08M15.23%
KCC2 library$692.00K5.06%
Other programs$590.00K4.31%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New OVID patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to OVID from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in OVID

VTIVanguard Morningstar Total Stock Market ETF$11.32M
IWMiShares Russell 2000 ETF$9.92M
XBIState Street SPDR S&P Biotech ETF$6.66M
VXFVanguard Extended Market ETF$5.18M
IWNiShares Russell 2000 Value ETF$3.15M
VTWOVanguard Russell 2000 ETF$2.47M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from OVID’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
0
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
2
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

IBRNiShares Neuroscience and Healthcare ETF0.68%
IWCiShares Micro-Cap ETF0.11%
XBIState Street SPDR S&P Biotech ETF0.07%
VFMOVanguard U.S. Momentum Factor ETF0.07%
AVNCAvantis All International Core Equity ETF0.06%
VMO.TOVanguard Global Momentum Factor ETF0.05%
FSEGFidelity Enhanced Small Cap Growth ETF0.03%
FESMFidelity Enhanced Small Cap ETF0.02%
PWSPacer WealthShield ETF0.02%
LABUDirexion Daily S&P Biotech Bull 3X Shares0.01%
BSVOEA Bridgeway Omni Small-Cap Value ETF0.01%

Weight is the stock’s share of each fund’s holdings.